# Cardiac Phase-Resolved T2* Magnetic Resonance Imaging Reveals Differences Between Normal Hearts and a Humanized Mouse Model of Hypertrophic Cardiomyopathy

**Authors:** Oumaima Laghzali, Shahriar Shalikar, Siqin Liu, Sandra Lehmann, Joao dos Santos Periquito, Andreas Pohlmann, Sonia Waiczies, Lucie Carrier, Hsin-Jung Yang, Thoralf Niendorf, Min-Chi Ku

PMC · DOI: 10.3390/biomedicines13051193 · Biomedicines · 2025-05-14

## TL;DR

This study shows that T2* MRI can detect heart differences in a mouse model of hypertrophic cardiomyopathy, suggesting it could help diagnose and monitor the disease.

## Contribution

The study introduces cardiac phase-resolved T2* MRI as a novel method for assessing hypertrophic cardiomyopathy in a humanized mouse model.

## Key findings

- Mybpc3-KI mice showed left-ventricular hypertrophy and reduced ejection fraction compared to wild-type mice.
- Myocardial T2* was significantly higher in HCM mice across all cardiac phases.
- T2* correlated strongly with left-ventricular mass in HCM mice.

## Abstract

Background/Objectives: While T2* mapping effectively assesses cerebral blood oxygenation, its utility for capturing cardiac phase-dependent myocardial changes in hypertrophic cardiomyopathy (HCM) is underexplored. This study investigates T2* dynamics in an HCM mouse model, to validate T2* as a clinically relevant biomarker for improved HCM diagnosis and treatment monitoring. Methods: A cardiac-specific Mybpc3 genetic mouse model, closely mirroring human HCM, was used with 12 young mice (6–11 weeks old), including both male and female wild-type (WT) and Mybpc3-KI (HCM) groups. The cardiac function was assessed using self-gated multi-slice 2D CINE imaging. To investigate myocardial T2* variations across the cardiac cycle, multi-gradient echo (MGE) imaging was employed. This approach used retrospective gating and continuous acquisition synchronization with pulse oximetry at 9.4 T small animal MRI. Results: Mybpc3-KI mice demonstrated left-ventricular (LV) hypertrophy compared to WT (HCM = 50.08 ± 4.68 µm/g vs. WT = 45.80 ± 20.07 µm/g, p < 0.01) and reduced ejection fraction (HCM = 38.55 ± 5.39% vs. WT= 72.53 ± 3.95%, p < 0.01). Myocardial T2* was significantly elevated in HCM across all cardiac phases (HCM = 12.14 ± 1.54 ms vs. WT = 7.93 ± 1.57 ms, p = 0.002). Strong correlations were observed between myocardial T2* and LV mass (rho = 0.88, p = 0.03). Conclusions: T2* was elevated in HCM with increased LV mass, highlighting the potential of T2* MRI as a sensitive biomarker for distinguishing healthy mice from those with HCM and revealing possible myocardial abnormalities.

## Linked entities

- **Genes:** MYBPC3 (myosin binding protein C3) [NCBI Gene 4607]
- **Diseases:** hypertrophic cardiomyopathy (MONDO:0005045)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Mybpc3 (myosin binding protein C, cardiac) [NCBI Gene 17868]
- **Diseases:** left-ventricular (LV) hypertrophy (MESH:D017379), HCM (MESH:D002312), myocardial abnormalities (MESH:D006330), LV mass (MESH:D018487)
- **Chemicals:** T (MESH:D014316)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12108774/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12108774/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC12108774/full.md

---
Source: https://tomesphere.com/paper/PMC12108774